NCT01035879 - Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Diabetes

Interventions

DRUG

MBX-2982

tablets and capsule once daily

DRUG

MBX-2982

tablets and capsule once daily

DRUG

MBX-2982

tablets and capsule once daily

DRUG

Sitagliptin

tablets and capsule once daily

DRUG

placebo

tablets and capsule once daily

Trial Locations (14)

10

Gandhi Endocrinology & Diabetes Centre, Rāmdaspeth

13901

United Medical Associates, Binghamton

78229

dgd Research, Inc., a Cetero Research Co., San Antonio

89101

Nevada Alliance Against Diabetes, Las Vegas

90036

Impact Clinical Trials, Los Angeles

132001

Bharti Research Institute of Diabetes and Endocrinology, Karnāl

201002

Hormone Care Research Centre, Ghaziabad

452001

Diabetes Thyroid Hormone Research Institute Pvt Ltd, Indore

560043

Medisys Clinisearch India Pvt Ltd, Bangalore

0144

Healthy Life Clinical Diagnostic Center, Tbilisi

0159

Georgian Diabetes Center, Tbilisi

0186

Medulla Chemotherapy and Immunotherapy Clinic, Tbilisi

560 054

Gokula Metropolis Research, MS Ramaiah Memorial Hospital, Bangalore

560 003

Bangalore Endocrinology & Diabetes Research Centre, Malleshwaram